William Palmer
Child & Adolescent Psychiatry · North Little Rock, ARNPI 1558469163
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 119 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 39.1% of the total. Reporting peaked in 2019 at $531 and has fallen 69.0% since, to $165 in 2025.
Across 119 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$707
- Johnson & Johnson$232
- Otsuka America Pharmaceutical, Inc.$161
- Ironshore Pharmaceuticals Inc.$99
- Lundbeck LLC$84
- Avanir Pharmaceuticals, Inc.$78
- plus $448 from 13 others
What the payments were for
- Food & beverage$1,809100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 52 | $707 |
| Johnson & Johnson | 15 | $232 |
| Otsuka America Pharmaceutical, Inc. | 10 | $161 |
| Ironshore Pharmaceuticals Inc. | 5 | $99 |
| Lundbeck LLC | 5 | $84 |
| Avanir Pharmaceuticals, Inc. | 5 | $78 |
| Supernus Pharmaceuticals, Inc. | 5 | $71 |
| Tris Pharma Inc | 4 | $68 |
| Eisai Inc. | 3 | $46 |
| Vanda Pharmaceuticals Inc. | 3 | $46 |
| Alkermes, Inc. | 2 | $44 |
| Bausch Health US, LLC | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Brainsway USA Inc | 1 | $27 |
| Sage Therapeutics, LLC | 1 | $18 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Neuronetics, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
How this compares
$1,809 in reported general payments places this provider in the 85th percentile of 24 child & adolescent psychiatry providers in Arkansas.
See all child & adolescent psychiatry providers in Arkansas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $550 |
| Aripiprazole | 13 | $392 |
| LoxapineLoxapine Succinate | 12 | $322 |
| Duloxetine Hcl | 19 | $264 |
| Lamotrigine | 17 | $192 |
| Olanzapine | 13 | $138 |
| Clonazepam | 20 | $78 |
| Zolpidem Tartrate | 12 | $33 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in North Little Rock
- Nihit KumarNorth Little Rock$306
- Jonathan SpradleyNorth Little Rock$125
- Ashley DumasLittle Rock$7K
- Ivan AldeaLittle Rock$5K
- Randall StaleySpringdale$3K
- Muhammad KhanJonesboro$1K
- Samuel BaylesLittle Rock$1K
- Saadia HaneefRogers$727
- Angela ShyLittle Rock$574
- Brandi YarberryLittle Rock$555
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.